Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Renizgamglogene autogedtemcel by Editas Medicine for Beta Thalassaemia: Likelihood of Approval
Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase II for Beta Thalassaemia. According to GlobalData,...
Renizgamglogene autogedtemcel by Editas Medicine for Sickle Cell Disease: Likelihood of Approval
Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase III for Sickle Cell Disease. According to...
Risk adjusted net present value: What is the current valuation of Editas Medicine's Renizgamglogene Autogedtemcel?
Renizgamglogene Autogedtemcel is a gene-modified cell therapy commercialized by Editas Medicine, with a leading Phase III program in Sickle Cell...